The University of Chicago Header Logo

Connection

Michael Bishop to Immunotherapy, Adoptive

Back to Details
This is a "connection" page, showing publications Michael Bishop has written about Immunotherapy, Adoptive.
Michael Bishop
Connection Strength
8.651
Immunotherapy, Adoptive
  1. Late complications and long-term care of adult CAR T-cell patients. Hematology Am Soc Hematol Educ Program. 2024 12 06; 2024(1):109-115.
    View in: PubMed
    Score: 0.767
  2. CAR T-cell therapy: A collaboration between authorized treatment centers and community oncologists. Semin Oncol. 2024 Jun-Aug; 51(3-4):87-94.
    View in: PubMed
    Score: 0.726
  3. Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma. N Engl J Med. 2022 02 17; 386(7):629-639.
    View in: PubMed
    Score: 0.624
  4. Clinical predictors of chimeric antigen receptor T-cell therapy neurotoxicity: a single-center study. Immunotherapy. 2021 10; 13(15):1261-1269.
    View in: PubMed
    Score: 0.614
  5. Current Status of CAR T Cell Therapy for Leukemias. Curr Treat Options Oncol. 2021 06 07; 22(7):62.
    View in: PubMed
    Score: 0.602
  6. Optimizing Administration of CAR T-Cell Therapy During the COVID-19 Pandemic. Clin Adv Hematol Oncol. 2020 07; 18(7):400-403.
    View in: PubMed
    Score: 0.564
  7. The benefit of CAR T cells in older patients. Blood. 2020 06 04; 135(23):2020-2021.
    View in: PubMed
    Score: 0.561
  8. Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance. J Immunother Cancer. 2018 12 04; 6(1):137.
    View in: PubMed
    Score: 0.506
  9. Two-stage CD8+ CAR T-cell differentiation in patients with large B-cell lymphoma. Nat Commun. 2025 May 06; 16(1):4205.
    View in: PubMed
    Score: 0.197
  10. Three-year analysis of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3. Leukemia. 2025 May; 39(5):1058-1068.
    View in: PubMed
    Score: 0.196
  11. Lisocabtagene maraleucel for relapsed/refractory large B-cell lymphoma: a cell therapy consortium real-world analysis. Blood Adv. 2025 Mar 11; 9(5):1232-1241.
    View in: PubMed
    Score: 0.195
  12. Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia. N Engl J Med. 2024 Dec 12; 391(23):2219-2230.
    View in: PubMed
    Score: 0.191
  13. Optimizing the post-CAR T monitoring period in recipients of axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel. Blood Adv. 2024 10 22; 8(20):5346-5354.
    View in: PubMed
    Score: 0.190
  14. Optimization of older adults by a geriatric assessment-guided multidisciplinary clinic before CAR T-cell therapy. Blood Adv. 2024 07 23; 8(14):3785-3797.
    View in: PubMed
    Score: 0.187
  15. Expert consensus guidelines on management and best practices for tumor-infiltrating lymphocyte cell therapy. J Immunother Cancer. 2024 02 29; 12(2).
    View in: PubMed
    Score: 0.182
  16. Adoptive immunotherapy with antigen-specific T cells in myeloma: a model of tumor-specific donor lymphocyte infusion. Semin Oncol. 2004 Feb; 31(1):37-46.
    View in: PubMed
    Score: 0.181
  17. Identifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphoma. Blood Adv. 2023 09 26; 7(18):5579-5585.
    View in: PubMed
    Score: 0.176
  18. Cost-Effectiveness of KTE-X19 for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in the United States. Adv Ther. 2022 08; 39(8):3678-3695.
    View in: PubMed
    Score: 0.162
  19. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021 10; 22(10):1403-1415.
    View in: PubMed
    Score: 0.153
  20. KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results. Blood. 2021 07 08; 138(1):11-22.
    View in: PubMed
    Score: 0.151
  21. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet. 2021 08 07; 398(10299):491-502.
    View in: PubMed
    Score: 0.150
  22. Management of hemophagocytic lymphohistiocytosis (HLH) associated with chimeric antigen receptor T-cell (CAR-T) therapy using anti-cytokine therapy: an illustrative case and review of the literature. Leuk Lymphoma. 2021 07; 62(7):1765-1769.
    View in: PubMed
    Score: 0.147
  23. Navigating Dilemmas in Treatment Choice: Our Approach to Supplemental Apheresis Prior to Enrollment in Early- Phase Cellular Therapy Clinical Trials. Transplant Cell Ther. 2021 02; 27(2):105-107.
    View in: PubMed
    Score: 0.146
  24. Chimeric Antigen Receptor T Cell Therapy During the COVID-19 Pandemic. Biol Blood Marrow Transplant. 2020 07; 26(7):1239-1246.
    View in: PubMed
    Score: 0.139
  25. The case for CAR T-cell therapy in follicular lymphomas. Blood. 2019 08 15; 134(7):577-578.
    View in: PubMed
    Score: 0.133
  26. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N Engl J Med. 2019 01 03; 380(1):45-56.
    View in: PubMed
    Score: 0.126
  27. Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'. Nat Rev Clin Oncol. 2018 04; 15(4):218.
    View in: PubMed
    Score: 0.120
  28. Phase I trial of adoptive cell transfer with mixed-profile type-I/type-II allogeneic T cells for metastatic breast cancer. Clin Cancer Res. 2011 Nov 01; 17(21):6878-87.
    View in: PubMed
    Score: 0.077
  29. Immunotherapy of metastatic breast cancer: phase I trail of reduced-intensity allogeneic hematopoietic stem cell transplantation with Th2/Tc2 T-cell exchange. Clin Breast Cancer. 2006 Apr; 7(1):87-9.
    View in: PubMed
    Score: 0.053
  30. Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALL. Blood Adv. 2024 Dec 10; 8(23):6139-6147.
    View in: PubMed
    Score: 0.048
  31. Allogeneic hematopoietic stem cell transplantation for metastatic breast cancer. Haematologica. 2004 May; 89(5):599-605.
    View in: PubMed
    Score: 0.046
  32. Axicabtagene Ciloleucel versus Tisagenlecleucel for Relapsed or Refractory Large B Cell Lymphoma: A Systematic Review and Meta-Analysis. Transplant Cell Ther. 2024 Jun; 30(6):584.e1-584.e13.
    View in: PubMed
    Score: 0.045
  33. Optimization of Metabolic Tumor Volume as a Prognostic Marker in CAR T-Cell Therapy for Aggressive Large B-cell NHL. Clin Lymphoma Myeloma Leuk. 2024 02; 24(2):83-93.
    View in: PubMed
    Score: 0.044
  34. Efficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: outcomes from 15 US institutions. Blood Adv. 2023 08 22; 7(16):4528-4538.
    View in: PubMed
    Score: 0.044
  35. Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3. J Immunother Cancer. 2023 08; 11(8).
    View in: PubMed
    Score: 0.044
  36. Low toxicity and excellent outcomes in patients with DLBCL without residual lymphoma at the time of CD19 CAR T-cell therapy. Blood Adv. 2023 07 11; 7(13):3192-3198.
    View in: PubMed
    Score: 0.043
  37. Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study. J Hematol Oncol. 2022 12 10; 15(1):170.
    View in: PubMed
    Score: 0.042
  38. Primary resistance to CD19-directed chimeric antigen receptor T-cell therapy in T-cell/histiocyte-rich large B-cell lymphoma. Blood. 2021 06 17; 137(24):3454-3459.
    View in: PubMed
    Score: 0.038
  39. High-Dose Sirolimus and Immune-Selective Pentostatin plus Cyclophosphamide Conditioning Yields Stable Mixed Chimerism and Insufficient Graft-versus-Tumor Responses. Clin Cancer Res. 2015 Oct 01; 21(19):4312-20.
    View in: PubMed
    Score: 0.025
  40. Minimal residual disease following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2011 Jan; 17(1 Suppl):S94-100.
    View in: PubMed
    Score: 0.018
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.